Optime Care
  • Home
  • About
  • Leadership
  • Stories
  • Careers
  • Contact
  • Home
  • About
  • Leadership
  • Stories
  • Careers
  • Contact

The Rare and Orphan Drug Commercialization Leader’s Guide to Patient Compliance

How a simple truth reimagines the management of orphan and rare disorders—for the benefit of all

You will learn:

  • The shortcomings of the legacy commercialization model
  • How a patients-first approach improves compliance and efficiency
  • 5 critical questions to ask your commercialization partners

“Optime Care is driving a patient compliance rate of nearly 90% for orphan and rare disease therapies. Compare that to industry standards of about 70% to 80% for specialty drugs and 50% for non-specialty or ‘regular’ drugs.”

– Michelle Hefley, Chairman of the Board and Managing Partner, Optime Care
Optime Care White Paper

Get Your Free White Paper

Stay Informed

Optime Care Newsletter Signup

Privacy Policy
Orange County Web Design by Website Muscle
© 2020 Optime Care